Can RAIL Predict Lupus Nephritis Course? - Scorecard - MDSpire

Can RAIL Predict Lupus Nephritis Course?

Urine biomarker index was associated with kidney inflammation and future treatment response across visits.

  • By

  • Andrea Surnit

  • April 27, 2026

  • 4 min

Share

Clinical Scorecard: Can RAIL Predict Lupus Nephritis Course?

At a Glance

CategoryDetail
ConditionLupus Nephritis
Key MechanismsUrine biomarker-based score predicting kidney inflammation and treatment response.
Target PopulationPatients with biopsy-proven active proliferative lupus nephritis.
Care SettingClinical trial setting.

Key Highlights

  • RAIL scores calculated from six urine biomarkers.
  • Demonstrated accuracy in identifying complete renal response.
  • Outperformed eGFR in distinguishing renal response states.
  • Higher RAIL scores associated with nonresponse at subsequent visits.
  • Noninvasive tool for assessing disease activity.

Guideline-Based Recommendations

Diagnosis

  • Use RAIL index alongside clinical measures to assess disease activity.

Management

  • Standard therapy with or without abatacept for lupus nephritis.

Monitoring & Follow-up

  • Monitor RAIL scores over time to predict treatment response.

Risks

  • Limitations include lack of repeat kidney biopsies and declining sample availability.

Patient & Prescribing Data

240 patients enrolled in the ALLURE trial.

RAIL scores improved over time, reflecting overall treatment response.

Clinical Best Practices

  • Consider baseline clinical factors when interpreting RAIL scores.
  • Utilize RAIL index for longitudinal assessment of lupus nephritis.

References

Original Source(s)

Can RAIL Predict Lupus Nephritis Course?

  • by Andrea Surnit

  • April 27, 2026

Related Content

FDA Clears Self-Administered Lupus Therapy

Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

Antibiotic Falls Short in Disc-Related Back Pain

A randomized trial found no greater pain reduction vs placebo, but questions remain about patients with type 1 Modic changes.